Last Price | 3.23 | Max Price | 6.51 |
Min Price | 0.36 | 1 Year return | 100.00 |
Sector | Health Care | Subsector | Biotechnology |
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 0 | 141,925 | 0.00 % |
2020 | 0 | 170,231 | 0.00 % |
2021 | 0 | 252,886 | 0.00 % |
2022 | 0 | 238,500 | 0.00 % |
2023 | 0 | 0 | 0.00 % |
No Records Found
No Records Found
No Records Found
The period between December 2015 and December 2016 was a loss-making period for the investors in Bio-Path Holdings. The stock lost around 38 percent. The period between August 2011 and August 2016 was a bad period for the investors. The stock lost around 0 percent.
Bio-Path Holdings primarily operates in the pharmaceutical sector. The global pharmaceutical companies gained around 75 percent worldwide over the last 10 years. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.
Bio-Path Holdings didn't pay out any dividends (in the past 5 years).
At the end of 2015 the pharmaceutical company's balance sheet was worth 0 million dollars. 0 million dollars ( percent of the total balance sheet) was financed by debt.
All Bio-Path Holdings's annual reports can be found here. More information about Bio-Path Holdings can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
0
|
0
|
0
|
0
|
0
|
|
Costs |
5
|
7
|
8
|
9
|
9
|
11
|
Profit |
-5
|
-7
|
-8
|
-9
|
-9
|
-11
|
Margin of profit |
0.0
|
-67500.00
|
-20150.00
|
0.0
|
0.0
|
|
ROI |
-55.70
|
-81.92
|
-99.88
|
-703.28
|
-40.78
|
-72.20
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
10
|
8
|
8
|
1
|
21
|
15
|
Debt |
1
|
4
|
1
|
1
|
2
|
1
|
Total assets |
11
|
12
|
9
|
3
|
23
|
16
|
Solvency |
91.26
|
67.54
|
91.08
|
47.84
|
93.07
|
91.44
|
Cash |
9
|
9
|
6
|
1
|
20
|
14
|
Cashflow |
-5
|
-8
|
-8
|
-6
|
-8
|
-11
|
Employees |
0
|
0
|
0
|
0
|
0
|
|
Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow / Debt |
-5.32
|
-2.06
|
-10.08
|
-4.60
|
-5.32
|
-7.77
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
250.00
|
270.00
|
40.50
|
3.50
|
7.99
|
Eps |
-14.56
|
-15.99
|
-14.38
|
-3.24
|
-2.83
|
Price/earnings-ratio |
-17.17
|
-16.89
|
-2.82
|
-1.08
|
-1.07
|
Dividend |
0.0
|
0.0
|
0.0
|
0.0
|
|
Dividend % |
0.00 %
|
0.00 %
|
0.00 %
|
0.00 %
|
|
Payout % |
0.0
|
0.0
|
0.0
|
0.0
|
|
Book value |
17.23
|
14.23
|
1.79
|
5.71
|
3.32
|
Market to book |
0.07
|
0.05
|
0.04
|
1.63
|
1.10
|
Cashflow per stock |
-17.04
|
-14.04
|
-9.00
|
-2.26
|
-2.41
|
Stocks |
0
|
1
|
1
|
4
|
5
|
Market Cap |
119.56
|
153.08
|
27.54
|
12.92
|
13.72
|
Date
|
Price
|
---|---|
17 Apr 2024
|
3.02
|
09 Apr 2024
|
3.92
|
05 Apr 2024
|
4.28
|
03 Apr 2024
|
4.41
|
30 Mar 2024
|
4.22
|
22 Mar 2024
|
4.23
|
18 Mar 2024
|
4.86
|
15 Mar 2024
|
5.12
|
12 Mar 2024
|
5.25
|
11 Mar 2024
|
5.83
|
09 Mar 2024
|
5.83
|
07 Mar 2024
|
6.51
|
01 Mar 2024
|
6.03
|
29 Feb 2024
|
6.03
|
27 Feb 2024
|
5.80
|
22 Feb 2024
|
0.44
|
21 Feb 2024
|
0.42
|
20 Feb 2024
|
0.43
|
15 Feb 2024
|
0.46
|
14 Feb 2024
|
0.46
|
13 Feb 2024
|
0.46
|
09 Feb 2024
|
0.45
|
08 Feb 2024
|
0.46
|
07 Feb 2024
|
0.47
|
06 Feb 2024
|
0.44
|
05 Feb 2024
|
0.44
|
01 Feb 2024
|
0.43
|
31 Jan 2024
|
0.43
|
30 Jan 2024
|
0.43
|
27 Jan 2024
|
0.43
|